Publication Cover
Annals of Tropical Paediatrics
International Child Health
Volume 12, 1992 - Issue 4
1
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Preterm infants with patent ductus arteriosus: treatment with an enteral preparation of indomethacin

, , &
Pages 403-408 | Received 21 Feb 1992, Published online: 13 Jul 2016

References

  • Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976; 295: 530–3.
  • Friedman WF, Hirscuklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976; 295: 526–9.
  • Halliday HL, Hirata T, Brady JP. Indomethacin therapy for large patent ductus arteriosus in the very low birth weight infant: results and complications. Pediatrics 1979; 64: 154–9.
  • Cooke RWI, Pickering D. Poor response to oral indomethacin therapy for persistent ductus arteriosus in very low birth weight infants. Br Heart J 1979; 41: 301–3.
  • Hallam HI, Kaltwinkel J, Park TS, Krovetz LJ. Failure of indomethacin to close persistent ductus arteriosus in infants weighing under 1000 grams. Br Heart J 1979; 41: 304–7.
  • Yeh TF, Luken JA, Thalji A, Raval D, Carr I, Pildes RS. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus—a double-blind controlled study. J Pediatr 1981; 98: 137–45.
  • Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102: 895–905.
  • Walters M. Tolerance of intravenous indomethacin treatment for premature infants with patent ductus arteriosus. Br Med J 1988; 297: 773–4.
  • Scholz TD, McGuiness GA. Localized intestinal perforation following intravenous indomethacin for patent ductus arteriosus. J Pediatr Gastroenterol Nutr 1988; 7: 773–5.
  • Reynolds JEF, Prasad AB, eds. Martindale The Extra Pharmacopoeia, 28th edn. 1982; 257–61.
  • Rudd P, Montanez P, Halklidie-Smith K, Silverman M. Indomethacin treatment for patent ductus arteriosus in very low birth weight infants: double blind trial. Arch Dis Child 1983; 58: 267–70.
  • Lewis IG, Harvey DP, Maxwell GM. Indomethacin therapy of patent ductus in preterm infants controlled by plasma level. Aust Paediatr J 1985; 21: 181–3.
  • Nagaraj HS, Sandhu AS, Cook LN, Buchino JJ, Groff DB. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg 1981; 16: 1003–7.
  • Alpan G, Eyal F, Vinograd I, et al. Localized intestinal perforations after enteral administration of indomethacin in premature infants. J Pediatr 1985; 106: 277–81.
  • Hervas JA, Masip MC, Alomar A, Bregante JI. Localized intestinal perforation after intravenous indomethacin in a premature infant. Helv Paediatr Acta 1986; 41: 437–40.
  • Scholz TD, McGuinness GA. Localized intestinal perforation following intravenous indomethacin for patent ductus arteriosus. J Pediatr Gastroenterol Nutr 1988; 5: 773–5.
  • Wolf WM, Snover DC, Leonard AS. Localized intestinal perforation following intravenous indomethacin in premature infants. J Pediatr Surg 1989; 24: 409–10.
  • Mellander M, Leheup B, Lindstrom DP, et al. Recurrence of symptomatic patent ductus arteriosus in extremely premature infants treated with indomethacin. J Pediatr 1984; 105: 138–43.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.